
Georgina V Long PhD FRACP; ESMO 2026: Neoantigen mRNA Vaccine Significantly Delays Recurrence in Patients with Resected Melanoma
Georgina V. Long AO PhD MBBS FRACP
MADRID, Spain—Individualized vaccination as adjuvant therapy for patients with stage two to four resected melanoma has achieved positive and highly encouraging outcomes according to findings from the INTerpath-001: Phase 3 study reported at the European Society for Medical Oncology 2026 congress. Patients in the study were randomized to treatment with the mRNA-based neoantigen therapy intismeran autogene added to standard immune checkpoint inhibitor adjuvant therapy, and compared with a control arm of patients receiving checkpoint inhibition alone.
Georgina V Long PhD FRACP; ESMO 2026: Neoantigen mRNA Significantly Delays Recurrence in Patients with Resected Melanoma
An interview with:
Georgina V Long AO PhD MBBS FRACP, Professor of Melanoma Medical Oncology and Translational Research, Medical Director, Melanoma Institute of Australia, University of Sydney, NSW, Australia
MADRID, Spain—Individualized vaccination as adjuvant therapy for patients with stage two to four resected melanoma has achieved positive and highly encouraging outcomes according to findings from the INTerpath-001: Phase 3 study reported at the European Society for Medical Oncology 2026 congress.
Patients in the study were randomized to treatment with the mRNA-based neoantigen therapy (INT) intismeran autogene added to standard immune checkpoint inhibitor adjuvant therapy, and compared with a control arm of patients receiving checkpoint inhibition alone.
Peter Goodwin heard the details from the study’s lead investigator, Georgina V Long AO PhD MBBS FRACP, Professor of Melanoma Medical Oncology and Translational Research, Medical Director,Melanoma Institute of Australia, University of Sydney, NSW, Australia
AUDIO JOURNAL OF ONCOLOGY; Georgina V. Long, PhD FRACP
Source:
ESMO Abstract:
LBA1 - INTerpath-001: Phase 3 study of the mRNA-based individualized neoantigen therapy (INT) intismeran autogene (intismeran) plus pembrolizumab (pembro) vs pembro alone for adjuvant treatment of resected stage IIB-IV melanoma (MEL)
Speaker
Georgina V. Long (Sydney, Australia)
More from ESMO 2026
All 4 interviewsThis is the last of the 4 ESMO 2026 interviews. See them all.
Related Episodes

Jacob Sands MD; ESMO 2026: Tarlatamab Bispecific Antibody Maintenance Therapy Prolongs Life for Patients with Extensive Stage Small Cell Lung Cancer
MADRID, Spain—Patients with extensive stage small cell lung cancer now have the green-light to add treatment with the bispecific antibody tarlatamab to their maintenance anti-PD-1 immunotherapy after first line chemo-immunotherapy induction. Results from the phase 3 DeLLphi-305 trial were reported at the 2026 Annual Congress of the European Society for Medical Oncology showing significantly improved overall and progression-free survival. Peter Goodwin spoke with study author Jacob Sands MD, Associate Chief of the Lowe Center for Thoracic Oncology at the Dana-Farber Cancer Institute, in Boston, USA, and Assistant Professor of Medicine at Harvard Medical School:

Rebecca Dent MD; ESMO 2026: Dato-DXd Brings Dramatic CNS Responses to Patients with Brain Metastases from Resected Inoperable or Metastatic Triple Negative Breast Cancer
MADRID, Spain—The antibody-drug conjugate datopotamab deruxtecan (aTrop-2-directed antibody carrying a topoisomerase inhibitor payload) achieved clinically meaningful intracranial responses among patients with resected inoperable or metastatic triple negative breast cancer with CNS involvement in the TROPION-Breast02 study discussed at the 2026 Annual Meeting of the European Society for Medical Oncology. Peter Goodwin heard the details from the study’s first author: Rebecca Dent MD, Senior Consultant Medical Oncologist and Deputy Chief Executive Officer at the National Cancer Centre in Singapore.

James Larkin PhD FRCP F Med Sci, ESMO 2026: Personalized mRNA Cancer Vaccines: Melanoma Study Success Provides Proof of Principle for Other Malignancies
MADRID, Spain— Personalized mRNA cancer vaccines for a range of tumor types are now seen as a realistic possibility thanks to mRNA technology already harnessed for treating melanoma in the phase III INTerpath-001 trial reported at the 2026 Annual Congress of the European Society for Medical Oncology. Peter Goodwin heard the latest on the potential of cancer vaccines from Scientific Co-Chair of ESMO 2026, James Larkin PhD FRCP F Med Sci, Head of The Royal Marsden Skin Unit, and Joint Training Programme Director for Medical Oncology and Lead of the Cancer Immunotherapy Theme at The Royal Marsden’s Institute of Cancer Research NIHR Biomedical Research Centre, in London UK.